News for Neuren Pharmaceuticals Limited (NEU.AX)

Good afternoon and welcome to the Thursday edition of Market Close, I’m Jonathon Davidson. It was a somewhat happier day as Australian icon Qantas paid its first dividend in years and household name Coles proved to be consistently growing.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. ”œWe closed 2

Neuren Pharmaceuticals is set to enter talks with the Us Food and Drug Administration about its upcoming trial.

One of the greatest recent films on share markets was The Big Short which was released in 2015. Starring Steve Carell, it did a fairly good job of

The local bourse gave up early gains and slipped into the red in afternoon trade, and did not return to positive territory.

ACADIA Pharmaceuticals Inc (ACAD) has announced the successful closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million,

Counting in the US election continues and markets are eagerly watching the results trickle in and are reacting accordingly.

The ASX200 closed up around 0.9% at 8,355 points after hitting a new record of 8,384 points in morning trade.

Mining giant Rio Tinto (ASX:RIO) has been down 1.5% on news it has made a takeover approach to Arcadium Lithium (ASX:LTM).

Neuren has confirmed it's received

The ASX200 closed up 1.25% at 7777.7 points, completing the second green session in a row. It has been a volatile time, and the market has finished the week by clawing back some, but not all, losses from the previous 5 sessions.

Neuren (ASX:NEU) was the biggest faller in lunchtime trades on Friday after announcing some children were "minimally improved" in phase 2 of a trial treating children with Angelman syndrome.

The ASX200 has finished 0.25 per cent higher, its second day of modest gains after a 3.7 per cent plunge on Monday.

Morgans healthcare analyst Scott Power said ASX health stocks have risen despite higher than expected inflation figures.

ACADIA Pharmaceuticals has a promising pipeline of drug candidates, including ACP-101 for Prader-Willi syndrome. Read why ACAD stock is a Buy.

The ASX200 didn’t seem to be able to recover from the CPI inflation data April read – showing a rise to 3.6 per cent – which was hotter than many had forecast. The index lost more than 1.15 per cent – all sectors were down with Consumer Staples, Industrials and Financials suffering the most.

Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome

In this article, we will be taking a look at the 20 biggest health care companies in Australia, 2024.

The ASX200 closed flat despite futures having tipped a moderate green day on market as investors endeavoured to digest the Australian CPI report.